- 工作地点：上海
- 职位：R＆D Scientist 研发科学家
- 信息来源：前程无忧(51JOB)
说明：
公司官网:ww***com[点击查看]
职能类别:生物工程/生物制药
此信息由前程无忧(51JOB)审核并发布（查看原发布网址），应届生求职网转载该信息只是出于传递更多就业招聘信息，促进大学生就业的目的。如您对此转载信息有疑义，请与原信息发布者前程无忧(51JOB)核实，并请同时联系本站处理该转载信息。
Responsibilities：
Manage study timelines, objectives and budgets, ensure data accuracy and integrity.
Analyze and interpret the data generated during discovery, early and/or full development; responsible for timely and effective communication of data, strategy and results to the project teams.
Identify potential project hurdles, suggest solutions and contribute to contingency plans.
Co-author and prepare key preclinical and clinical, and regulatory documents, scientific manuscripts and patent application,including, but not limited to: study protocols, study reports, modeling reports, investigator brochures, IND/IMPDs and NDAs within agreed timelines, and meeting all regulatory requirements.
Works collaboratively within cross-departmental teams, department-wide initiatives and work streams.
Provide cell therapy expertise on due diligence of BD projects and prepare appropriate documentation.
Adhere to the appropriate SOP and GxP guidelines, and embrace a collaborative culture
Requirments：
PhD and/or MD, strong scientific background in immunology or oncology, international Post-doctoral training is an advantage
Pharmaceutical industry R&D work experience is an advantage
Ability to analyze data, trouble-shoot, train and work closely with other functions
Good written, spoken and interpersonal communication skills in Chinese and English required.
公司简要介绍：
公司名称:Kite Pharma
公司类型:上市公司
公司介绍:"To bring about this transformation, we're developing innovative products that harness a patient's own immune system to target and attack cancer cells. In just three years, our singular focus and strategic collaborations, including multiple Cooperative Research and Development Agreements with the National Cancer Institute, have enabled us to advance an industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to address both hematological (blood-based) and solid cancers.
On October 3, 2017, Kite became a Gilead company with the completion of the acquisition by Gilead Sciences.
"
